These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 12214266

  • 1. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.
    Oncogene; 2002 Sep 12; 21(41):6255-63. PubMed ID: 12214266
    [Abstract] [Full Text] [Related]

  • 2. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG.
    Cancer Res; 2006 Jan 01; 66(1):404-11. PubMed ID: 16397255
    [Abstract] [Full Text] [Related]

  • 3. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 5. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
    Xia W, Liu LH, Ho P, Spector NL.
    Oncogene; 2004 Jan 22; 23(3):646-53. PubMed ID: 14737100
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL.
    Oncogene; 2005 Sep 15; 24(41):6213-21. PubMed ID: 16091755
    [Abstract] [Full Text] [Related]

  • 9. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
    Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS.
    Cancer Res; 2002 Aug 01; 62(15):4307-15. PubMed ID: 12154034
    [Abstract] [Full Text] [Related]

  • 10. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
    Murillo H, Schmidt LJ, Tindall DJ.
    Cancer Res; 2001 Oct 15; 61(20):7408-12. PubMed ID: 11606371
    [Abstract] [Full Text] [Related]

  • 11. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
    Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L.
    Cancer Res; 2003 Nov 15; 63(22):7777-84. PubMed ID: 14633703
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. H2O2-induced transactivation of EGF receptor requires Src and mediates ERK1/2, but not Akt, activation in renal cells.
    Zhuang S, Schnellmann RG.
    Am J Physiol Renal Physiol; 2004 May 15; 286(5):F858-65. PubMed ID: 15075181
    [Abstract] [Full Text] [Related]

  • 14. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL, Xia W, Spector NL.
    Clin Cancer Res; 2008 Nov 01; 14(21):6730-4. PubMed ID: 18980964
    [Abstract] [Full Text] [Related]

  • 15. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J.
    Cancer Res; 2001 Sep 01; 61(17):6500-10. PubMed ID: 11522647
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY, Lee SW, Hong JP, Chang SE, Choe H, Choi J.
    Cancer Lett; 2009 Oct 08; 283(2):135-42. PubMed ID: 19380191
    [Abstract] [Full Text] [Related]

  • 17. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N, Fujiwara T.
    FEBS Lett; 2005 Aug 01; 579(19):4069-75. PubMed ID: 16023108
    [Abstract] [Full Text] [Related]

  • 18. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM, Saigal B, Donato NJ.
    J Cell Physiol; 2005 Nov 01; 205(2):218-27. PubMed ID: 15887238
    [Abstract] [Full Text] [Related]

  • 19. EGF-dependent cell cycle progression is controlled by density-dependent regulation of Akt activation.
    LeVea CM, Reeder JE, Mooney RA.
    Exp Cell Res; 2004 Jul 01; 297(1):272-84. PubMed ID: 15194442
    [Abstract] [Full Text] [Related]

  • 20. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y, Poon RT, Shao W, Sun X, Chen H, Kok TW, Fan ST.
    Cancer Lett; 2007 Apr 08; 248(1):32-40. PubMed ID: 16837130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.